Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-Human Study of KAND145 in Healthy Volunteers
NCT06063343Phase 1Completed
- Sponsor
- Kancera
- Start
- Nov 2023
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of fosrugocrixan in ovarian cancer (4 arms), sponsored by Kancera. Primary endpoints: Incidence of Adverse Events, Vital Signs and 7 more. Started Nov 2023; status: completed.
02
Drugs
fosrugocrixan
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT06063343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06063343.